Avidity Biosciences Inc (RNA)

$38.33

-1.27

(-3.21%)

Market is closed - opens 7 PM, 20 Jun 2024

Insights on Avidity Biosciences Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.19M → 3.54M (in $), with an average increase of 38.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -47.02M → -68.85M (in $), with an average decrease of 13.6% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 241.2% return, outperforming this stock by 193.5%

Performance

  • $38.10
    $39.73
    $38.33
    downward going graph

    0.6%

    Downside

    Day's Volatility :4.1%

    Upside

    3.52%

    downward going graph
  • $4.83
    $42.00
    $38.33
    downward going graph

    87.4%

    Downside

    52 Weeks Volatility :88.5%

    Upside

    8.74%

    downward going graph

Returns

PeriodAvidity Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
65.48%
0.6%
0.0%
6 Months
352.05%
8.9%
0.0%
1 Year
241.09%
10.2%
0.0%
3 Years
47.71%
17.8%
-20.9%

Highlights

Market Capitalization
3.8B
Book Value
$8.69
Earnings Per Share (EPS)
-2.96
PEG Ratio
0.0
Wall Street Target Price
62.25
Profit Margin
0.0%
Operating Margin TTM
-2178.58%
Return On Assets TTM
-20.38%
Return On Equity TTM
-32.91%
Revenue TTM
10.9M
Revenue Per Share TTM
0.14
Quarterly Revenue Growth YOY
58.699999999999996%
Gross Profit TTM
-141.2M
EBITDA
-252.8M
Diluted Eps TTM
-2.96
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.2
EPS Estimate Next Year
-3.41
EPS Estimate Current Quarter
-0.78
EPS Estimate Next Quarter
-0.78

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Avidity Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 62.41%

Current $38.33
Target $62.25

Company Financials

FY18Y/Y Change
Revenue
379.0K
↓ 97.1%
Net Income
-11.9M
-
Net Profit Margin
-3.1K%
-
FY19Y/Y Change
Revenue
2.3M
↑ 511.87%
Net Income
-32.1M
↑ 169.16%
Net Profit Margin
-1.4K%
↑ 1763.69%
FY20Y/Y Change
Revenue
6.8M
↑ 192.67%
Net Income
-44.0M
↑ 36.93%
Net Profit Margin
-648.03%
↑ 737.09%
FY21Y/Y Change
Revenue
9.3M
↑ 37.41%
Net Income
-117.4M
↑ 166.86%
Net Profit Margin
-1.3K%
↓ 610.49%
FY22Y/Y Change
Revenue
9.2M
↓ 1.09%
Net Income
-169.1M
↑ 44.05%
Net Profit Margin
-1.8K%
↓ 574.49%
FY23Y/Y Change
Revenue
9.6M
↑ 3.64%
Net Income
-212.2M
↑ 25.52%
Net Profit Margin
-2.2K%
↓ 386.86%
Q4 FY22Q/Q Change
Revenue
2.8M
↑ 11.56%
Net Income
-47.7M
↑ 12.89%
Net Profit Margin
-1.7K%
↓ 20.24%
Q1 FY23Q/Q Change
Revenue
2.2M
↓ 19.36%
Net Income
-47.2M
↓ 1.1%
Net Profit Margin
-2.1K%
↓ 390.13%
Q2 FY23Q/Q Change
Revenue
2.3M
↑ 3.72%
Net Income
-47.0M
↓ 0.35%
Net Profit Margin
-2.0K%
↑ 82.95%
Q3 FY23Q/Q Change
Revenue
2.8M
↑ 21.68%
Net Income
-52.4M
↑ 11.34%
Net Profit Margin
-1.9K%
↑ 172.46%
Q4 FY23Q/Q Change
Revenue
2.2M
↓ 22.18%
Net Income
-60.4M
↑ 15.44%
Net Profit Margin
-2.8K%
↓ 898.2%
Q1 FY24Q/Q Change
Revenue
3.5M
↑ 61.56%
Net Income
-68.9M
↑ 13.92%
Net Profit Margin
-1.9K%
↑ 812.77%
FY18Y/Y Change
Total Assets
4.0M
↓ 96.82%
Total Liabilities
45.1M
↑ 18.7%
FY19Y/Y Change
Total Assets
96.9M
↑ 2333.63%
Total Liabilities
162.3M
↑ 259.7%
FY20Y/Y Change
Total Assets
333.9M
↑ 244.56%
Total Liabilities
27.7M
↓ 82.94%
FY21Y/Y Change
Total Assets
427.6M
↑ 28.06%
Total Liabilities
46.2M
↑ 66.76%
FY22Y/Y Change
Total Assets
638.8M
↑ 49.4%
Total Liabilities
60.7M
↑ 31.58%
FY23Y/Y Change
Total Assets
628.6M
↓ 1.6%
Total Liabilities
127.8M
↑ 110.44%
Q4 FY22Q/Q Change
Total Assets
638.8M
↑ 48.37%
Total Liabilities
60.7M
↑ 13.38%
Q1 FY23Q/Q Change
Total Assets
614.0M
↓ 3.89%
Total Liabilities
55.1M
↓ 9.33%
Q2 FY23Q/Q Change
Total Assets
610.8M
↓ 0.52%
Total Liabilities
51.6M
↓ 6.27%
Q3 FY23Q/Q Change
Total Assets
573.2M
↓ 6.16%
Total Liabilities
55.7M
↑ 7.92%
Q4 FY23Q/Q Change
Total Assets
628.6M
↑ 9.66%
Total Liabilities
127.8M
↑ 129.45%
Q1 FY24Q/Q Change
Total Assets
951.5M
↑ 51.37%
Total Liabilities
120.6M
↓ 5.65%
FY18Y/Y Change
Operating Cash Flow
-9.7M
-
Investing Cash Flow
-49.0K
-
Financing Cash Flow
5.1M
↓ 94.16%
FY19Y/Y Change
Operating Cash Flow
2.5M
↓ 125.79%
Investing Cash Flow
-235.0K
↑ 379.59%
Financing Cash Flow
89.2M
↑ 1634.7%
FY20Y/Y Change
Operating Cash Flow
-37.1M
↓ 1590.64%
Investing Cash Flow
-7.8M
↑ 3212.77%
Financing Cash Flow
272.0M
↑ 204.86%
FY21Y/Y Change
Operating Cash Flow
-94.8M
↑ 155.44%
Investing Cash Flow
-82.5M
↑ 959.95%
Financing Cash Flow
176.3M
↓ 35.19%
FY22Y/Y Change
Operating Cash Flow
-136.3M
↑ 43.72%
Investing Cash Flow
-190.0M
↑ 130.2%
Financing Cash Flow
346.2M
↑ 96.34%
Q4 FY22Q/Q Change
Operating Cash Flow
-39.2M
↑ 22.62%
Investing Cash Flow
-7.8M
↓ 171.06%
Financing Cash Flow
243.7M
↑ 514.98%
Q1 FY23Q/Q Change
Operating Cash Flow
-49.0M
↑ 24.95%
Investing Cash Flow
46.0M
↓ 692.8%
Financing Cash Flow
23.0M
↓ 90.58%
Q2 FY23Q/Q Change
Operating Cash Flow
-49.8M
↑ 1.72%
Investing Cash Flow
46.0M
↑ 0.0%
Financing Cash Flow
39.0M
↑ 69.73%

Technicals Summary

Sell

Neutral

Buy

Avidity Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Avidity Biosciences Inc
Avidity Biosciences Inc
35.43%
352.05%
241.09%
47.71%
76.71%
Moderna, Inc.
Moderna, Inc.
-2.21%
61.44%
11.0%
-30.77%
776.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.88%
22.86%
33.81%
94.34%
240.92%
Novo Nordisk A/s
Novo Nordisk A/s
5.61%
41.82%
73.65%
241.2%
437.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
6.24%
17.06%
38.23%
152.16%
166.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Avidity Biosciences Inc
Avidity Biosciences Inc
NA
NA
0.0
-3.2
-0.33
-0.2
NA
8.69
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.72
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.58
30.58
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.48
49.48
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.16
31.16
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Avidity Biosciences Inc
Avidity Biosciences Inc
Buy
$3.8B
76.71%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$53.7B
776.11%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.2B
240.92%
30.58
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
437.92%
49.48
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.1B
166.21%
31.16
39.46%

Institutional Holdings

  • FMR Inc

    14.89%
  • RTW INVESTMENTS, LLC

    8.33%
  • T. Rowe Price Associates, Inc.

    7.77%
  • BlackRock Inc

    6.45%
  • venBio Select Advisor LLC

    6.09%
  • COWEN AND COMPANY, LLC

    5.89%

Corporate Announcements

  • Avidity Biosciences Inc Earnings

    Avidity Biosciences Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

avidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated

Organization
Avidity Biosciences Inc
Employees
253
CEO
Dr. Troy Edward Wilson J.D., Ph.D.
Industry
Health Technology

FAQs